CGEM insider transaction filings
Cullinan Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-10. Screen CGEM transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 5 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 3 filings by 1 insider — 46,000 shares, $922,920 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 8.
- Largest priced transaction: sale of 30,000 shares @ $20.26 ($607,800) by Michaelson Jennifer, filed 2026-08-14.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Michaelson Jennifer — Chief Scientific Officer | 3 | — | 3 legs · 46,000 sh · $922,920 | 6 |
| Fenton Mary Kay — Chief Financial Officer | 1 | — | — | 1 |
| SUMER JACQUELYN L — Chief Legal Officer | 1 | — | — | 1 |
Recent Form 4 filings — Cullinan Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-10 | 4 | Michaelson Jennifer — Chief Scientific Officer | Option exercise (M): 4,000 @ $4.30 · Sale (S): 8,000 @ $21.57 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2026-08-14 | 4 | Michaelson Jennifer — Chief Scientific Officer | Option exercise (M): 30,000 @ $4.30 · Sale (S): 30,000 @ $20.26 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2026-07-07 | 4 | Michaelson Jennifer — Chief Scientific Officer | Option exercise (M): 4,000 @ $4.30 · Sale (S): 8,000 @ $17.82 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | SUMER JACQUELYN L — Chief Legal Officer | Grant/award (A): 2,470 @ $8.60 | EDGAR |
| 2026-07-02 | 4 | Fenton Mary Kay — Chief Financial Officer | Grant/award (A): 1,541 @ $8.60 | EDGAR |
| 2026-06-18 | 4 | Doyle Mittie — Director | Grant/award (A): 21,781 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Meek David D. — Director | Grant/award (A): 25,319 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Rosenberg Anthony — Director | Grant/award (A): 25,319 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Webster Stephen W — Director | Grant/award (A): 25,319 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Allen Andrew R — Director | Grant/award (A): 21,781 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Thistle Mary — Director | Grant/award (A): 25,319 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | Michaelson Jennifer — Chief Scientific Officer | Option exercise (M): 4,000 @ $4.30 · Sale (S): 7,800 @ $14.60 · Sale (S): 200 @ $15.58 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Michaelson Jennifer — Chief Scientific Officer | Option exercise (M): 4,000 @ $4.30 · Sale (S): 8,000 @ $15.68 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2026-02-26 | 4 | Michaelson Jennifer — Chief Scientific Officer | Sale (S): 1,780 @ $14.14 | EDGAR |
| 2026-02-25 | 4 | Michaelson Jennifer — Chief Scientific Officer | Sale (S): 1,752 @ $13.99 · Sale (S): 3,601 @ $14.47 | EDGAR |
| 2026-02-25 | 4 | Jones Jeffrey Alan — Chief Medical Officer | Sale (S): 4,582 @ $14.47 | EDGAR |
| 2026-02-25 | 4 | SUMER JACQUELYN L — Chief Legal Officer | Sale (S): 3,601 @ $14.47 | EDGAR |
| 2026-02-25 | 4 | AHMED NADIM — President and CEO, Director | Sale (S): 13,515 @ $14.47 | EDGAR |
| 2026-02-23 | 4 | Jones Jeffrey Alan — Chief Medical Officer | Sale (S): 4,982 @ $13.62 | EDGAR |
| 2026-02-23 | 4 | Michaelson Jennifer — Chief Scientific Officer | Sale (S): 3,742 @ $13.62 · Option exercise (M): 8,000 @ $4.30 · Sale (S): 8,000 @ $14.30 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2026-02-23 | 4 | SUMER JACQUELYN L — Chief Legal Officer | Sale (S): 3,742 @ $13.62 | EDGAR |
| 2026-02-23 | 4 | AHMED NADIM — President and CEO, Director | Sale (S): 16,381 @ $13.62 | EDGAR |
| 2026-02-23 | 4 | Fenton Mary Kay — Chief Financial Officer | Sale (S): 4,398 @ $13.62 | EDGAR |
| 2026-02-19 | 4 | SUMER JACQUELYN L — Chief Legal Officer | Grant/award (A): 230,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Jones Jeffrey Alan — Chief Medical Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Savill Corrine — Chief Business Officer | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Michaelson Jennifer — Chief Scientific Officer | Grant/award (A): 57,500 @ $0 · Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | AHMED NADIM — President and CEO, Director | Grant/award (A): 828,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Fenton Mary Kay — Chief Financial Officer | Grant/award (A): 68,750 @ $0 · Grant/award (A): 137,500 (derivative) @ $0 | EDGAR |
| 2026-02-13 | 4 | Michaelson Jennifer — Chief Scientific Officer | Sale (S): 416 @ $12.03 | EDGAR |
| 2026-01-23 | 4 | Michaelson Jennifer — Chief Scientific Officer | Sale (S): 4,000 @ $12.30 | EDGAR |
| 2026-01-05 | 4 | Fenton Mary Kay — Chief Financial Officer | Grant/award (A): 27 @ $6.49 | EDGAR |
| 2025-12-29 | 4 | AHMED NADIM — President and CEO, Director | Sale (S): 9,922 @ $10.01 | EDGAR |
| 2025-12-22 | 4 | Michaelson Jennifer — Chief Scientific Officer | Sale (S): 1,345 @ $10.01 | EDGAR |
| 2025-12-19 | 4 | SUMER JACQUELYN L — Chief Legal Officer | Sale (S): 3,480 @ $9.67 | EDGAR |
| 2025-12-19 | 4 | Jones Jeffrey Alan — Chief Medical Officer | Sale (S): 4,632 @ $9.67 | EDGAR |
| 2025-12-19 | 4 | Michaelson Jennifer — Chief Scientific Officer | Sale (S): 2,898 @ $9.67 | EDGAR |
| 2025-12-16 | 4 | Michaelson Jennifer — Chief Scientific Officer | Sale (S): 2,148 @ $12.38 · Sale (S): 995 @ $11.90 | EDGAR |
| 2025-11-25 | 4 | Michaelson Jennifer — Chief Scientific Officer | Sale (S): 4,000 @ $12.30 | EDGAR |
| 2025-10-30 | 4 | Lynx1 Capital Management LP — 10% owner Nichols Weston — 10% owner | Purchase (P): 165,667 @ $8.40 | EDGAR |
| 2025-10-21 | 4 | Lynx1 Capital Management LP — 10% owner Nichols Weston — 10% owner | Purchase (P): 15,032 @ $7.59 · Purchase (P): 51,500 @ $7.94 · Purchase (P): 150,000 @ $8.86 · Purchase (P): 32,217 @ $7.84 | EDGAR |
| 2025-10-10 | 4 | Lynx1 Capital Management LP — 10% owner Nichols Weston — 10% owner | Purchase (P): 556,300 @ $6.46 · Purchase (P): 626,043 @ $6.70 · Purchase (P): 277,298 @ $7.36 | EDGAR |
| 2025-08-08 | 4 | Doyle Mittie — Director | Grant/award (A): 79,456 (derivative) @ $0 | EDGAR |
| 2025-08-08 | 4 | Allen Andrew R — Director | Grant/award (A): 79,456 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Ryan David P. — Director | Grant/award (A): 38,513 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Martin Anne-Marie — Director | Grant/award (A): 38,513 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Meek David D. — Director | Grant/award (A): 38,513 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Rosenberg Anthony — Director | Grant/award (A): 38,513 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Webster Stephen W — Director | Grant/award (A): 38,513 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | AHMED NADIM — President and CEO, Director | Sale (S): 12,529 @ $8.53 | EDGAR |
Recent 8-K events — Cullinan Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-14 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-10 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-08 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-18 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-08 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CGEM returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →